
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has demonstrated robust growth with a 7% year-over-year increase despite challenging comparisons, indicating strong market demand for its liquid-based cancer tests. The company's commanding market position is highlighted by its over 50% share in the circulating genomic profiling liquid biopsy segment and nearly 30% year-over-year growth in this area, along with anticipated increases in average selling prices and test volumes from new reimbursements and pricing strategies. Additionally, Guardant's proactive approach to expand testing frequency and services suggests a promising trajectory for revenue growth, positioning the company favorably within the evolving landscape of cancer diagnostics.
Bears say
The financial analysis of Guardant Health indicates a negative outlook primarily due to concerns surrounding reimbursement dynamics, which are expected to pressure the average selling price (ASP) and pose direct risks to revenue estimates. Additionally, the pending implementation of PAMA regulations could lead to a significant one-time revenue reduction of approximately $100 million, further compounding the company’s financial challenges. Furthermore, uncertainties in the regulatory landscape for multi-cancer early detection (MCED) tests may hinder reimbursement and adoption of Guardant's assays, ultimately affecting the company's profitability and future outlook.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares